SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of BELLUS Health Inc (Nasdaq – BLU)

BALA CYNWYD – April 18, 2023 /Newsfile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of BELLUS Health Inc (“BELLUS” or the “Company”) (Nasdaq – BLU) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by GSK Plc (NYSE – GSK). Under the terms of the Agreement, BELLUS shareholders will receive $14.75 cash for each BELLUS common share, for a total equity value of approximately $2.0 billion.

The investigation concerns whether the BELLUS Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether GSK Plc is paying too little for the Company.

If you own shares of BELLUS stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.